has chosen Advanced Chemistry Development, Inc., (ACD/Labs) to provide them
with an integrated analytical data management system for their enterprise. ACD/Labs'
global spectroscopic processing and data management software, ACD/SpecManager
SQL, will be implemented at Boehringer Ingelheim's research and development
facilities in Vienna, Ingelheim, and Biberach, providing each location with
the tools necessary to access, process, organize, and manage various types of
experimental data through a single interface.
is a powerful yet simple-to-use tool for storing and managing various types
of experimental spectra and chromatograms, as well as any related information.
Its central database module, ACD/SpecDB, is paired with processing modules for
various analytical techniques, including the NMR, MS, UV-IR, and chromatography
modules chosen by Boehringer Ingelheim. Together, the ACD/SpecManager suite
of products will work seamlessly as one comprehensive module, providing more
information and greater capabilities then would be provided by the simple sum
of its parts.
ACD/SpecManager SQL will add Oracle-based client-server architecture to Boehringer Ingelheim's SpecManager modules, enabling several users to work with the same database simultaneously, and ensuring the seamless integration of analytical data and results from Boehringer Ingelheim's various research and development facilities. One of the major factors in Boehringer Ingelheim's decision to implement ACD/SpecManager SQL was this ability to share data across different sites in a consistent file format.
will also benefit from the ability to use previously purchased ACD/Labs software
for systematic naming and physicochemical property prediction from within the
SpecManager interface, enabling users to generate names and calculate physicochemical
properties for the structures attached to each database record.
Dr. Andreas Ding,
Department of Analytics at BI's Biberach, Germany facility, states, "The
integration of the ACD/Labs software into our workflow has given us the functionality
of a modern enter-prise wide Analytical Data Management System. This allows
us to handle various analytical data and results in an efficient way, and grants
us the ability to instantly share this know-ledge enterprise-wide. In the field
of spectral verification and structure elucidation, we have taken the first
step into automated spectra verification and computer assistant structure elucidation
"Enterprise-Wide management of legacy analytical data and associated chemical structures offers the opportunity to dramatically impact the quality and pace of structural identification at Boehringer Ingelheim," comments Antony Williams, VP of Scientific Development and Marketing for ACD/Labs. "We are confident that the solution we have delivered will offer significant return on investment in a short period of time and will positively impact the processes BI scientists adopt for identifying chemical structures."
Advanced Chemistry Development
Development, Inc., (ACD/Labs) is a chemistry software company offering solutions
that truly integrate chemical structures with analytical chemistry information
to produce ChemAnalyticsTM. ACD/Labs creates innovative software packages that
aid chemical research scientists worldwide with spectroscopic validation of
structures, elucidation of unknown substances, chromatographic separation, medicinal
chemistry, preformulation of novel drug agents, systematic nomenclature generation,
and chemical patenting and publication. Combined, ACD/Labs' solutions create
an analytical informatics system that provides dramatic feed-forward effects
on the chemical and pharmaceutical research process. Founded in 1993, and headquartered
in Toronto, Canada, ACD/Labs employs a team of over 100 dedicated individuals
whose continual efforts carry ACD/Labs' innovative technologies into pharmaceutical,
biotech, chemical, and materials companies throughout the world. Information
about Advanced Chemistry Development and its products can be found at www.acdlabs.com.
The Boehringer Ingelheim Corporation is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 156 affiliates in 44 countries and a total of about 32,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine. In 2002, Boehringer Ingelheim posted net sales of 7.6 billion euro while spending about one fifth of net sales in its largest business segment Prescription Medicines on research and development. For more information on Boehringer Ingelheim, please see the international Internet website www.boehringer-ingelheim.com.